Abstract

Since the introduction of propranolol (Inderal -ICI) two more β -adrenergic receptor blocking agents have become available for clinical use, practolol (Eraldin - ICI) and oxprenolol (Trasicor - Ciba). Both manufacturers claim that their product is less likely than propranolol to precipitate heart failure or asthma. All three drugs, although structurally similar, have different pharmacological properties which are summarised in the table. The use of the drugs in different clinical situations must therefore be considered separately.